The study shows that acini (AS-ih-nye), the small milk-producing elements in breast lobules, can be counted in sample biopsies. The percentage of acini present per lobule at a given age indicates cancer risk. Researchers say this method is more accurate in predicting risk for an individual than the Gail model (see National Cancer Institute).
“Aside from the predictors of heredity, there is no effective independent predictor of risk of breast cancer,” says Lynn Hartmann, M.D., Mayo Clinic oncologist and senior author of the study. “This risk estimate model based on novel tissue in each individual may provide a reliable strategy.”
Researchers studied the tissue structures in 85 patients with breast cancer and examined earlier, noncancerous breast biopsies from the same women. They compared them to 142 age-controlled samples from Mayo’s Benign Breast Disease Cohort, a bio repository of benign biopsy tissues. Then, researchers developed the model and tested a risk prediction for each patient. For the same women, they used the existing Gail model to make five-year risk predictions for the same women. While helpful in determining increased risk in groups of women, the Gail model is only slightly better than a guess when it comes to predicting cancer for an individual, the researchers say.
“Women who were more likely to develop breast cancer had larger lobules with more acini,” explains Dr. Hartmann.
Significance of the Findings
As women age, especially as they approach menopause, the risk of breast cancer declines because the lobules and acini disappear. This natural process, called involution, is at the core of this risk factor. Dr. Hartmann says if the lobules aren’t largely gone by the time a woman is 55, her risk of breast cancer triples. By looking closely at the structures in a large sample of benign tissues, the researchers were able to note standard measurements for lobule size and number of acini in the lobules. This twofold approach led to development of accurate metrics on which to base individual risk. The team hopes this new model, combined with other patient information and assessments, will greatly improve a physician’s ability to predict cancer risk for individual patients.
Others on the research team are Kevin McKian, M.D.; Carol Reynolds, M.D.; Daniel Visscher, M.D.; Aziza Nassar, M.D.; Derek Radisky, Ph.D.; Robert Vierkant; Amy Degnim, M.D.; Judy Boughey, M.D.; Karthik Ghosh, M.D.; Stephanie Anderson; Douglas Minot; Jill Caudill; Celine Vachon, Ph.D.; Marlene Frost, Ph.D.; and V. Shane Pankratz, Ph.D.; all of Mayo Clinic. The research was supported by the Department of Defense, Martha and Bruce Atwater, the National Institutes of Health, and the Fred C. and Katherine B. Andersen Foundation.
About Mayo Clinic
Mayo Clinic is the first and largest integrated, not-for-profit group practice in the world. Doctors from every medical specialty work together to care for patients, joined by common systems and a philosophy of “the needs of the patient come first.” More than 3,300 physicians, scientists and researchers and 46,000 allied health staff work at Mayo Clinic, which has sites in Rochester, Minn., Jacksonville, Fla., and Scottsdale/Phoenix, Ariz. Collectively, the three locations treat more than half a million people each year. To obtain the latest news releases from Mayo Clinic, go to www.mayoclinic.org/news. For information about research and education visit www.mayo.edu. MayoClinic.com is available as a resource for your health stories.